DOI QR코드

DOI QR Code

Pharmacological Treatment Strategies for Acute Bipolar Depression

급성기 양극성우울증 약물치료 전략

  • Kim, Se Joo (Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine)
  • 김세주 (연세대학교 의과대학 정신건강의학교실, 의학행동과학연구소)
  • Received : 2018.10.08
  • Accepted : 2018.11.07
  • Published : 2018.11.30

Abstract

Of the different phases of bipolar disorder, bipolar depression is more prevailing and is more difficult to treat. However, there is a deficit in systemic research on the pharmacological treatment of acute bipolar depression. Therefore, consensuses on the pharmacological treatment strategies of acute bipolar depression has yet to be made. Currently, there are only three drugs approved by the Food and Drug Administration for acute bipolar depression : quetiapine, olanzapine-fluoxetine complex, and lurasidone. In clinical practice, other drugs such as mood stabilizers (lamotrigine, lithium, valproate) and/or the other atypical antipsychotics (aripiprazole, risperidone, ziprasidone) are frequently prescribed. There remains controversy on the use of antidepressants in bipolar depression. Here, we summarized the evidence of current pharmacological treatment options and reviewed treatment guidelines of acute bipolar depression from recently published studies.

Keywords

Acknowledgement

본 논문의 일부는 미래창조과학부 한국연구재단(NRF)의 이공분야 기초연구사업의 연구비 지원에 의해 이루어진 것입니다(Grant number : 2018R1A2B2007714).